This GLP-1 Receptor Agonist for weight loss exclusion existed for Pennsylvania ACA Small Group & Individual and Small Group Grand-mothered in North Eastern PA already Weight loss medications, including GLP-1s FDA approved for weight loss , will automatically be excluded from coverage as a standard benefit beginning with December 1, 2024 plan renewal dates and upon renewals occurring thereafter for the following newly impacted PA segments: PA Fully Insured Large Group ( unless specifically meeting grandfathered status requirements ) PA Fully Insured Small Group Grand-mothered in Western PA and Central PA Coverage of GLP-1s FDA approved for diabetes will not be impacted, although some Authorizations or Medical Management may apply
Long-term concerns include the loss of muscle mass, the likelihood of weight regain after stopping therapy, and potential risks such as arthritis and pancreatitis
The tumor in the 16 cases had an average maximum diameter of 8.55 cm, with a median of 5.7 cm, compared to a previous study reporting a median tumor size of 3.2 cm [2]
This typically affects people who are overweight or who have insulin resistance such as diabetes patients
(5) treatment duration of GLP-1 RAs 12 years
More frequent monitoring may be needed with oral semaglutide due to the known pharmacokinetic interaction that increases levothyroxine exposure by approximately 33%
:max_bytes(150000):strip_icc()/insulin-injection-478185779-594b3cae3df78cae8111498f.jpg)
